ReviewCancer cell international2021
Crosstalk between MUC1 and VEGF in angiogenesis and metastasis: a review highlighting roles of the MUC1 with an emphasis on metastatic and angiogenic signaling.
Review in Cancer cell international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 56 citations in OpenAlex.
- SGMHA: semantic graph reconstruction with multi-head attention for gene regulatory network inference.BMC genomics · 2026Article
- Nintedanib Eye Drops Inhibit Alkali Burn-Induced Corneal Neovascularization Via RAP1/MEK/ERK Signaling Pathway.Investigative ophthalmology & visual science · 2026Article
- Marine nutraceuticals and their role in modulating diabetes-induced carcinogenesis.Diabetology & metabolic syndrome · 2026Review
- Review
- Deciphering Deleterious nsSNPs in MUC16's SEA Domain: Structural and Functional Implications in Cancer Metastasis via Computational Analysis.Journal of cellular and molecular medicine · 2025Article
- Nanotherapeutic Formulations for the Delivery of Cancer Antiangiogenics.Molecular pharmaceutics · 2025Review
- The Oncoprotein Mucin 1 in Pancreatic Cancer Onset and Progression: Potential Clinical Implications.Biomolecules · 2025Review
- Management of Regorafenib-Induced Hand-Foot Skin Reaction with Topical Chinese Medicine and Urea Ointment: A Case Report and Literature Review.OncoTargets and therapy · 2025Article
- Astragaloside IV: a potential nemesis for gastric cancer.Frontiers in pharmacology · 2025Review
- The multifaceted roles of mucins family in lung cancer: from prognostic biomarkers to promising targets.Frontiers in immunology · 2025Review
- CAR-T cell therapy for the treatment of adult high-grade gliomas.NPJ precision oncology · 2024Review
- Molecular Targets of Plant-Derived Bioactive Compounds in Oral Squamous Cell Carcinoma.Cancers · 2024Review
- The crosstalk role of CDKN2A between tumor progression and cuproptosis resistance in colorectal cancer.Aging · 2024Article
- Article
- Article
- NSUN2 affects diabetic retinopathy progression by regulating MUC1 expression through RNA mJournal of translational medicine · 2024Article
- Review
- Role of PATJ in stroke prognosis by modulating endothelial to mesenchymal transition through the Hippo/Notch/PI3K axis.Cell death discovery · 2024Article
- The effect of gD-derived peptides on T cell immune response mediated by BTLA-HVEM protein complex in melanoma patients.Frontiers in immunology · 2024Article
- Machine learning identifies a 5-serum cytokine panel for the early detection of chronic atrophy gastritis patients.Cancer biomarkers : section A of Disease markers · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
VEGF and its receptor family (VEGFR) members have unique signaling transduction system that play significant roles in most pathological processes, such as angiogenesis in tumor growth and metastasis. VEGF-VEGFR complex is a highly specific mitogen for endothelial cells and any de-regulation of the angiogenic balance implicates directly in endothelial cell proliferation and migration. Moreover, it has been shown that overexpressing Mucin 1 (MUC1) on the surface of many tumor cells resulting in upregulation of numerous signaling transduction cascades, such as growth and survival signaling pathways related to RTKs, loss of cell-cell and cell-matrix adhesion, and EMT. It promotes gene transcription of pro-angiogenic proteins such as HIF-1α during periods of oxygen scarcity (hypoxia) to enhance tumor growth and angiogenesis stimulation. In contrast, the cytoplasmic domain of MUC1 (MUC1-C) inhibits apoptosis, which in turn, impresses upon cell fate. Besides, it has been established that reduction in VEGF expression level correlated with silencing MUC1-C level indicating the anti-angiogenic effect of MUC1 downregulation. This review enumerates the role of MUC1-C oncoprotein and VEGF in angiogenesis and metastasis and describes several signaling pathways by which MUC1-C would mediate the pro-angiogenic activities of cancer cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.